Valneva: CHMP recommends extended indication for Ixchiq

(CercleFinance.com) - Valneva announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending authorization of the extension of the indication of IXCHIQ vaccine, Valneva's single-injection vaccine for the prevention of disease caused by the chikungunya virus, to people aged twelve and over.


IXCHIQ® had already received marketing authorization in Europe for people aged 18 and over in July 20241.

The European Commission (EC) will now examine the CHMP's recommendation, and a decision on the application to extend the vaccine's indication in the European Union (EU), Norway, Liechtenstein and Iceland is expected within sixty days.

Copyright (c) 2025 CercleFinance.com. All rights reserved.